Biocon vs Gland Pharma: Which Stock Should You Track

Biocon MCap Rs 69,262 Cr, PE 188.05x, ROE 1.14%, D/E 0.45. Gland Pharma MCap Rs 41,996 Cr, PE 40.88x, ROE 9.92%, D/E 0.03.

Updated: 10 Aug 2026 • 10:42 am

Posted by:

Biocon vs Gland Pharma: Which Stock Should You Track

Biocon vs Gland Pharma is a comparison biopharma and specialty pharma investors look up when evaluating two Indian companies with differentiated exposure to biologics and injectables. Biocon is one of India's largest biopharma companies, known for insulin, biosimilars of major biologics and its joint venture Biocon Biologics, while Gland Pharma is India's largest injectables manufacturer for export, majority-owned by Chinese pharma giant Fosun Pharma, with a B2B model selling to major global generic companies.

This Biocon vs Gland Pharma article covers reach and market position, key products, latest declared results and stock valuation. The Biocon vs Gland Pharma data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Table of Contents

Biocon vs Gland Pharma: Reach and Market Position

On the Biocon side of the Biocon vs Gland Pharma comparison, Biocon operates biosimilar and small molecule manufacturing in Bangalore and has Biocon Biologics as a key subsidiary focused on global biosimilar launches across markets including the US, Europe and Emerging Markets. Market capitalisation is Rs 69,262 Cr.

Click Here – Get Free Investment Predictions

On the Gland Pharma side of the Biocon vs Gland Pharma comparison, Gland Pharma manufactures injectables — vials, ampoules, prefilled syringes and bags — for B2B export customers including major US and European generic companies. Market capitalisation is Rs 41,996 Cr.

Biocon vs Gland Pharma: Key Products and Business Mix

In the Biocon vs Gland Pharma product comparison, Biocon offers: Biocon earns from insulin APIs and formulations, biosimilars of adalimumab, trastuzumab and bevacizumab, and small molecule APIs. EPS is Rs 2.26. P/E is 188.05x, ROE 1.14 percent, D/E 0.45. Very thin earnings due to biosimilar investment phase.

For Gland Pharma in this Biocon vs Gland Pharma breakdown: Gland Pharma earns from injectable formulations in vials, ampoules, prefilled syringes and bags. EPS is Rs 62.27. P/E is 40.88x, ROE 9.92 percent, D/E 0.03.

Biocon vs Gland Pharma: Latest Results

The Biocon vs Gland Pharma results for Biocon: Biocon has a market cap of Rs 69,262 Cr and P/E of 188.05x. ROE is 1.14 percent — extremely low due to the thin earnings during the biosimilar commercialisation investment phase. The high P/E is a long-duration bet on biosimilar adoption in the US and Europe.

The Biocon vs Gland Pharma results for Gland Pharma: Gland Pharma has a market cap of Rs 41,996 Cr and P/E of 40.88x. ROE is 9.92 percent with near-zero debt. Gland's B2B injectable model generates stable revenues but growth depends on partner demand and new product approvals.

Compare Biocon and Gland Pharma Fundamentals on the Univest Screener

Biocon vs Gland Pharma: Stock and Valuation

The Biocon vs Gland Pharma stock comparison uses the latest available market data from Groww. Investors tracking Biocon vs Gland Pharma should verify current prices on NSE or BSE before trading.

Biocon vs Gland Pharma at current valuations: Biocon trades at Rs 69,262 Cr market cap, P/E 188.05x, ROE 1.14 percent. Gland Pharma trades at Rs 41,996 Cr market cap, P/E 40.88x, ROE 9.92 percent. Biocon is 1.6 times larger by market cap but has much lower current ROE and far higher P/E due to biosimilar optionality pricing.

Biocon vs Gland Pharma: Quick Comparison Table

The Biocon vs Gland Pharma comparison table below summarises the key metrics covered in this article side by side.

Parameter	Biocon	Gland Pharma
Sector	Biopharma: biosimilars + insulin	Injectables CDMO/B2B (US + global export)
Market Cap	Rs 69,262 Cr	Rs 41,996 Cr
P/E Ratio	188.05x (optionality priced)	40.88x
ROE	1.14% (investment phase)	9.92%
Debt to Equity	0.45	0.03
Business Model	B2C biosimilar + API sales	B2B injectable manufacturer
Promoter	Kiran Mazumdar-Shaw (founder)	Fosun Pharma (China), 57% stake

Conclusion

The Biocon vs Gland Pharma comparison above covers the key data points on reach, products, results and valuation. Biocon vs Gland Pharma is a comparison between a biosimilar optionality play and a steady B2B injectable manufacturer. Biocon is a high-risk, high-potential bet on global biosimilar adoption. Gland Pharma is a cash-generative injectable specialist with a B2B model and near-zero debt. Both face different risk profiles. Investors should review Biocon's biosimilar sales traction in the US and Europe, and Gland's partner concentration, injectable approval pipeline and Fosun-related risks before taking a view. Consult a SEBI-registered advisor for personalised guidance.

Download the Univest iOS App or Univest Android App to track Biocon and Gland Pharma live price and get daily stock recommendations.

SEBI Research Analyst Registration No. INH000013776

Frequently Asked Questions

What is a biosimilar?

Ans. A biosimilar is a biological medicine that is highly similar to an approved innovator biological drug and has no clinically meaningful differences. Biosimilars of molecules like adalimumab (Humira), trastuzumab (Herceptin) and bevacizumab (Avastin) can be sold at lower prices after the innovator's patent expires.

What does Gland Pharma make?

Ans. Gland Pharma manufactures injectable pharmaceutical products including vials, ampoules, pre-filled syringes and infusion bags. It primarily supplies to third-party generic companies in the US and Europe under a B2B model.

Who owns Gland Pharma?

Ans. Gland Pharma is majority-owned by Fosun Pharma (China), which acquired a controlling stake in 2019. Gland Pharma is listed on Indian exchanges.

What is Biocon Biologics?

Ans. Biocon Biologics is a subsidiary of Biocon focused on developing and commercialising biosimilars globally, including adalimumab (Hadlima), trastuzumab (Ogivri) and others.

Why is Biocon's ROE so low?

Ans. Biocon's ROE of 1.14 percent reflects thin current earnings as the company is in a heavy investment phase for biosimilar global launches, regulatory filings and capacity building. Investors evaluate Biocon on long-term biosimilar revenue potential.